Literature DB >> 32510588

Saliva Pepsin Concentration of Laryngopharyngeal Reflux Patients Is Influenced by Meals Consumed Before the Samples.

Alexandra Rodriguez1,2, Sven Saussez1,3,2, Jerome R Lechien1,3,4,2, Francois Bobin1,5, Vinciane Muls1,6, Mihaela Horoi2, Marie-Paule Thill2, Didier Dequanter1,2, Camille Finck1,7.   

Abstract

OBJECTIVES/HYPOTHESIS: To assess the impact of diet on the saliva pepsin concentration of patients with laryngopharyngeal reflux (LPR). STUDY
DESIGN: Non-controlled Prospective Study.
METHODS: Patients with positive LPR regarding hypopharyngeal-esophageal impedance-pH monitoring (HEMII-pH) were enrolled from three European Hospitals. Patients collected three saliva samples, respectively, in the morning (fasting), and 1 to 2 hour after lunch and dinner. Patients carefully detailed foods and beverages consumed during meals and before the pepsin samples. The 3-month treatment was based on the association of diet, proton pump inhibitors, alginate, or magaldrate regarding the HEMII-pH characteristics. Reflux Symptom Score (RSS) and Reflux Sign Assessment (RSA) were used for assessing the pre- to posttreatment clinical evolution. The Refluxogenic Diet Score and the Refluxogenic Score of a Dish (RESDI) were used to assess the refluxogenic potential of foods and beverages. The relationship between saliva pepsin concentration, HEMII-pH, RESDI, RSS, and RSA was investigated through multiple linear regression.
RESULTS: Forty-two patients were included. The saliva pepsin concentration of the 24-hour period of testing was significantly associated with foods and beverages consumed during the testing period and the evening dinner (rs = 0.973, P < .001). RSS and RSA significantly improved throughout treatment. The level of saliva pepsin in the morning was a negative predictive factor of the therapeutic response regarding RSA and RSS (P < .036).
CONCLUSIONS: Foods and beverages may significantly impact the saliva pepsin concentration of patients with LPR. Patients with high-level saliva pepsin in the morning had lower therapeutic response compared with those with low-level saliva pepsin. LEVEL OF EVIDENCE: 4 Laryngoscope, 131:350-359, 2021.
© 2020 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  Reflux; beverages; diet; foods; laryngitis; laryngopharyngeal; pepsin; saliva

Mesh:

Substances:

Year:  2020        PMID: 32510588     DOI: 10.1002/lary.28756

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

1.  The study of laryngopharyngeal reflux needs adequate animal model.

Authors:  Jerome R Lechien; Christian Calvo-Henriquez; Miguel Mayo-Yanez; Mariam El Ayoubi; Luigi A Vaira; Antonino Maniacci
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-02-19       Impact factor: 2.503

2.  The importance of 24-h hypopharyngeal-esophageal impedance-pH monitoring for the treatment of laryngopharyngeal reflux.

Authors:  Robin Baudouin; Christian Calvo-Henriquez; Miguel Mayo-Yanez; Giannicola Iannella; Antonino Maniaci; Jerome R Lechien
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-08-25       Impact factor: 3.236

3.  In response to the importance of 24-h hypopharyngeal-esophageal impedance-pH monitoring for the treatment of laryngopharyngeal reflux.

Authors:  Jinhong Zhang; Xiaoyu Wang; Jiasen Wang; Jing Zhao; Chun Zhang; Zhi Liu; Jinrang Li
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-08-27       Impact factor: 3.236

Review 4.  Laryngopharyngeal Reflux: A State-of-the-Art Algorithm Management for Primary Care Physicians.

Authors:  Jerome R Lechien; Sven Saussez; Vinciane Muls; Maria R Barillari; Carlos M Chiesa-Estomba; Stéphane Hans; Petros D Karkos
Journal:  J Clin Med       Date:  2020-11-10       Impact factor: 4.241

5.  Do Otolaryngologists Over- or Underestimate Laryngopharyngeal Reflux Symptoms and Findings in Clinical Practice? A Comparison Study between the True Prevalence and the Otolaryngologist-Estimated Prevalence of Symptoms and Findings.

Authors:  Jerome R Lechien
Journal:  J Clin Med       Date:  2022-09-01       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.